News
Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...
Fifteen of the biotechnology company’s products delivered at least double-digit sales growth in the second quarter.
Non-GAAP earnings per share for Q2 2025 beat estimates by 14.0%, rising to $6.02 (non-GAAP) and up 21% year over year (non-GAAP). Revenue increased 9% to $9.2 billion, exceeding analyst expectations ...
Amgen narrowed its 2024 adjusted earnings estimate and now expects a profit of $19.10 to $20.10 per share, compared with its previous view of $19.00 to $20.20.
Analysts had expected $6.17 per share on revenue of $16.4 billion. Amgen’s shares rose $3.51, or 4.4 percent, to $82.80 after hours, on top of a 1.7 percent gain during regular trading.
BOSTON (CBS.MW) -- Amgen's fourth-quarter net profit jumped 20 percent, as higher drug sales fueled a 33 percent rise in revenue, the world's largest biotechnology firm reported late Thursday.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback